Abstracts tagged "skin"

Abstract Number: 0848 • ACR Convergence 2025
Spatial Frequency Domain Imaging (SFDI) for Skin Assessment in Systemic Sclerosis: Insights from Histology and Clinical Correlates
Hung Vo¹, Aarohi Mehendale², Martin Azzam³, Fatima-Ezzahrae El Adili⁴, Rutvi Patel³, Marcin TROJANOWSKI³, Michael York⁵, Eugene Kissin⁶, Jeffrey Browning⁷, Jag Bhawan³, Darren Roblyer⁵ and Andreea Bujor⁵, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Boston University School of Medicine, Revere, MA, ⁵Boston University, Boston, MA, ⁶Boston University, Newton, MA, ⁷Boston University School of Medicine, Cambridge, MA
Background/Purpose: Assessing skin involvement in systemic sclerosis (SSc) is complex, with no single method capturing all pathological changes. The modified Rodnan Skin Score (mRSS) is…
Abstract Number: 1757 • ACR Convergence 2025
Skin-to-Joint Immune Cell Migration and Synovial Reprogramming in Psoriatic Arthritis Onset
Maria Gabriella Raimondo¹, Hashem Mohammadian², Mario Angeli², Vladyslav Fedorchenko², Kaiyue Huang³, Yi-Nan Li⁴, Raphael Micheroli⁵, Jörg Distler⁶, Ursula Fearon⁷, Juergen Rech², Francesco Ciccia⁸, Juan Cañete⁹, Adam Croft¹⁰, Mariola Kurowska-Stolarska¹¹, Stefano Alivernini¹², Maria Antonietta D'Agostino¹³, Georg Schett², Simon Rauber¹⁴ and Andreas Ramming¹⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰University of Birmingham, Hagley, Stourbridge, United Kingdom, ¹¹University of Glasgow, Glasgow, ¹²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹³Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ¹⁵Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Psoriatic arthritis (PsA) develops in about 30% of individuals with psoriasis (PsO), highlighting a critical connection between skin and joint inflammation. However, the mechanisms…
Abstract Number: 0846 • ACR Convergence 2025
A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification
Rezvan Parvizi¹, Zhiyun Gong², Natania Field³, Helen Jarnagin², Dillon Popovich², Monica Yang⁴, Kathleen Aren⁵, Mary Carns⁶, Isaac Goldberg⁷, Lorinda Chung⁸, Vivien Goh⁹, Zsuzsanna McMahan¹⁰, Tammara Wood¹¹, Dinesh Khanna¹², Monique Hinchcliff¹³ and Michael Whitfield¹⁴, ¹Dartmouth, lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Northwestern Memorial Hospital, Chicago, IL, ⁴UCSF, San Francisco, CA, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Wayne State University, Detroit, ⁸Stanford University, Stanford, CA, ⁹Northwestern, Chicago, ¹⁰UT Health Houston, Houston, TX, ¹¹Dartmouth, Hanover, NH, ¹²University of Michigan, Ann Arbor, MI, ¹³Yale School of Medicine, Westport, CT, ¹⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Mycophenolate Mofetil (MMF) is the most commonly prescribed immunosuppressive treatment for patients diagnosed with diffuse cutaneous systemic sclerosis (dcSSc). Here, we analyzed skin gene…
Abstract Number: 1571 • ACR Convergence 2025
Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
Ifeoluwa Emmanuel Bamigbola¹, Jayakumar Vadakekolathu¹, Stefano Di Donato², Vishal Kakkar³, Rebecca Ross⁴, Yasser El-Sherbiny¹ and Francesco Del Galdo³, ¹¹Nottingham Trent University, Department of Biosciences, School of Science and Technology, Nottingham, United Kingdom, ²University of Leeds, Canosa Sannita, Chieti, Italy, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: The skin from patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) already exhibits fibrotic alterations such as collagen deposition and perivascular infiltration (1),…
Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
Abstract Number: 1823 • ACR Convergence 2024
Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts
Zhiyun Gong¹, Rezvan Parvizi², Helen Jarnagin¹, Haobin Chen³, Madeline Morrisson⁴, Tammara Wood⁵, Monique Hinchcliff⁶ and Michael Whitfield², ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵Dartmouth, Hanover, NH, ⁶Yale School of Medicine, Westport, CT
Background/Purpose: Systemic Sclerosis (SSc) is a molecularly heterogeneous disease. Distinct subtypes of patients have been identified based on gene expression in skin. In this study,…
Abstract Number: 2512 • ACR Convergence 2024
French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy
Kevin Chevalier¹, François Chasset², Yoann Zerbib³, Pierre-André Jarrot⁴, Romain Muller⁴, Thomas Pires⁵, Saroumadi Adavane⁶, Didier Bessis⁷, Alban Deroux⁸, Vincent Descamps⁹, Fanny Domont¹⁰, Joëlle Faddoul¹⁰, Pierre-Edouard gavand¹¹, Tiphaine Goulenok¹², Baptiste Gramont¹³, Vincent Jachiet¹⁴, Gaëlle Leroux¹⁵, Matthieu Mahevas¹⁶, Julie Merindol¹⁷, Loïc Meudec¹⁸, Martin Michaud¹⁹, Morgane Mourguet²⁰, Héloïse Munos pons²¹, Yann Nguyen²², Bénédicte Oules²³, Thomas Papo²⁴, Jacques Pouchot²⁵, Sébastien Rivière¹⁴, Oscar Robert²⁶, Charles ronsin²⁷, Benjamin Rossi²⁸, Delphine Staumont-salle²⁹, Benjamin Terrier³⁰, Nathalie Tieule³¹, Vollmer Olivier³², Pierre Wolkenstein³³, Xavier Puéchal³⁴, Jean-David Bouaziz³⁵, Nicolas Dupin²³, Gilles Peytavin³⁶, Jean-Claude Alvarez³⁷, Luc Mouthon³⁸ and Alexis Régent³⁴, ¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, ²Dermatology, Hôpital Tenon, Paris, France, ³Medical Intensive Care Unit and MP3CV-EA7517, Amiens University Hospital, Amiens, France, Amiens, France, ⁴Service de Médecine Interne et Immunologie Clinique, Hôpital de La Conception, Marseille, Marseille, France, ⁵Department of Internal Medicine, CHU Bordeaux, Bordeaux, France., Bordeaux, France, ⁶Service de Cardiologie, Hôpitaux Saint-Antoine and Tenon, AP-HP, 75012 Paris, France., Paris, France, ⁷Department of Dermatology and Reference Center for Rare Skin Diseases (MAGEC), Saint-Eloi Hospital, University of Montpellier and INSERM U1058, Montpellier, France., Montpellier, France, ⁸Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁹Department of Dermatology, APHP, Bichat Hospital, Paris, France., Paris, France, ¹⁰AP-HP. Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose Inflammatoire, F-75013 Paris, France., Paris, France, ¹¹Department of Internal Medicine, Clinique Rhena, Strasbourg, France., Strasbourg, France, ¹²Assistance Publique Hôpitaux de Paris, Paris, France, ¹³Internal Medicine Departement, Saint Etienne, Saint Etienne, France, ¹⁴Service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Universite, Paris, France., Paris, France, ¹⁵Service de Médecine Interne, AP-HP Hôpital Pitié-Salpêtrière, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, APHP, Mondor Hospital, Paris, France., Créteil, France, ¹⁷Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ¹⁸Department of Rheumatology, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France., Kremlin Bicêtre, France, ¹⁹Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, ²⁰service de médecine interne CHU Toulouse RANGUEIL, Toulouse, France, ²¹Department of Internal Medicine, Saint-Etienne University Hospital, Saint-Etienne, France., Saint Etienne, France, ²²Université Paris Saclay, Clichy, Ile-de-France, France, ²³Dermatology Department, Cochin Hospital, Paris, France., Paris, France, ²⁴Université Paris Cité, Paris, France, ²⁵Service de médecine Interne, Centre National de Référence des syndromes drépanocytaires majeurs de l'adulte, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, Paris, France, ²⁶Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France; [email protected]., Paris, France, ²⁷cHD Vendée, La Roche sur Yon, La Roche sur Yon, France, ²⁸Service de médecine interne, maladies infectieuses, Centre hospitalier intercommunal de Robert Ballenger, Aulnay-sous-bois, France., Aulnay-sous-bois, France, ²⁹Service de dermatologie, CHU de Lille, université de Lille, 59000 Lille, France., Lille, France, ³⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ³¹Rhumatologie, Centre Hospitalier Universitaire Nice, Hôpital Pasteur, Nice, France, ³²Department of Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France., Strasbourg, France, ³³Department of Dermatology, National Referral Center for Neurofibromatosis, Henri Mondor University Hospital, Assistance Publique- Hôpitaux de Paris, Creteil, France., Créteil, France, ³⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France., Paris, France, ³⁶Service de Pharmacologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France., Paris, France, ³⁷Service de Pharmacologie‑Toxicologie, Hôpital Raymond Poincaré, Groupe Hospitalier Universitaires AP-HP.Paris-Saclay, Garches, 92380, France, Paris, France, ³⁸Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Levamisole, an imidazothiazole formerly used as an anthelmintic, is also used as a cutting agent to enhance the effects and duration of cocaine. In…
Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Richard Warren¹, April W. Armstrong², Shinichi Imafuku³, Akimichi Morita⁴, Carle Paul⁵, Matthias Augustin⁶, Thierry Passeron⁷, Leon Kircik⁸, Eleni Vritzali⁸, Thomas Scharnitz⁹, Georgene Schroeder⁹, Subhashis Banerjee¹⁰ and Bruce Strober¹¹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²University of California Los Angeles, Los Angeles, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵Toulouse University and CHU, Toulouse, France, ⁶Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Bristol Myers Squibb, Princeton, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 1825 • ACR Convergence 2024
Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
Abstract Number: 2549 • ACR Convergence 2024
VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light
Zachary Peters¹, Lindsay Mendyka², Angelique Cortez¹, J'voughnn Blake¹, Alecia Roy¹, William Rigby³, Christopher Burns⁴, Randolph Noelle⁵ and Sladjana Skopelja-Gardner⁶, ¹Dartmouth College, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Dartmouth-Hitchcock, Norwich, VT, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Geisel School of Medicine at Dartmouth, Lebanon, ⁶Dartmouth Geisel School of Medicine, Lebanon, NH
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of cutaneous lupus erythematosus (CLE) that is exacerbated by ultraviolet (UV) light.…
Abstract Number: 1137 • ACR Convergence 2024
Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Kristina Callis Duffin¹, Christopher E. M. Griffiths², Matthias Hoffmann³, Andrew Blauvelt⁴, Eugene Balagula⁵, Andrew Napoli⁵, Ying-Ming Jou⁵, Rachel Dyme⁵, Virginia Hala⁵, andreas pinter⁶ and Mark Lebwohl⁷, ¹University of Utah, Salt Lake City, ²Dermatology Centre, University of Manchester, Manchester, and King’s College Hospital and King’s College London, London, United Kingdom, ³Private Practice, Witten, Germany, ⁴Oregon Medical Research Center, Portland, OR, ⁵Bristol Myers Squibb, Princeton, ⁶University Hospital of the Goethe University, Frankfurt am Main, Frankfurt, Germany, ⁷Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US, EU, and other countries for treatment of adults with…
Abstract Number: 1830 • ACR Convergence 2024
Single-cell RNA Sequencing Profiling of Very Early-Stage Systemic Sclerosis Skin Reveals a Fibroblast Pro-inflammatory Gene Signature and Keratinocyte Dysregulation
Lumeng Li¹, Elena Pachera², Rucsandra Dobrota³, Kristina Bürki¹, Carina Mihai³, Muriel Elhai⁴, Laura Much¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Sarah Lötscher⁷, Anna-Maria Hoffmann-Vold⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University Hospital zurich, Zürich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Norway, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The poor prognosis of patients with systemic sclerosis (SSc) underscores the need to prevent disease onset and irreversible organ damage. This study aims to…
Abstract Number: 2655 • ACR Convergence 2024
Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses
Aaron Bao¹, Eleni Tiniakou², Lisa Christopher-Stine³, Christopher Mecoli³, Jemima Albayda¹, Julie Paik³, William Kelly⁴ and Jun Kang⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Lutherville Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Hillsboro, NH, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is often misdiagnosed due to its diverse clinical presentation. This study aimed to identify common dermatologic mimics of DM, characterize misdiagnosis rates…
Abstract Number: 0084 • ACR Convergence 2024
DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
Xi Li, bing Li, Jun Yao, bin zhang, zhongyuan zhu, yang Qiu and haiqing Hua, Duality Biologics Ltd, Shanghai, China (People's Republic)
Background/Purpose: BDCA2 (blood dendritic cell antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), whose over-production of type I interferon (IFN-I) is crucial in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].